CLINICAL TRIALS PROFILE FOR DRISDOL
✉ Email this page to a colleague
All Clinical Trials for DRISDOL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00882401 ↗ | Vitamin D, Chronic Kidney Disease (CKD) and the Microcirculation | Completed | Barts & The London NHS Trust | Phase 4 | 2009-04-01 | Overall research aims: This study will examine the effect of vitamin D supplementation on the function of the endothelium and microcirculation of patients with chronic kidney disease and vitamin D deficiency. Hypothesis: Vitamin D therapy in patients with CKD and concomitant vitamin D deficiency will improve endothelial, and therefore microcirculatory function, reduce levels of oxidative stress and thus reduce the risk of future CVS events in this population. |
| NCT01004354 ↗ | Vitamin D Supplementation in Psychiatric Illnesses | Completed | University of Massachusetts, Worcester | N/A | 2009-06-01 | Children and adolescents with psychiatric illnesses who are treated with medications called second generation antipsychotic agents (SGA) often gain excessive weight during their treatment with these medications. This weight gain may result in the development of features of the metabolic syndrome or frank diabetes mellitus. There is no consensus on the best way to prevent these complications. The investigators' hypothesis is that daily vitamin D supplementation in these patients will result in decreased levels of the markers of metabolic syndrome with associated reduction in waist circumference. |
| NCT01153243 ↗ | Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes | Unknown status | Rush University | Phase 4 | 2007-04-01 | Recent clinical trials in non diabetics showed that vitamin D supplementation markedly reduced serum levels of C-reactive protein (CRP), interleukin-6, and tissue matrix metallo-proteinases. Our study objective is to evaluate if administration of vitamin D in African Americans with hypovitaminosis D and DM Type 2 decreases serum levels of inflammatory/thrombotic markers such as CRP: Highly Sensitive C Reactive Protein. |
| NCT01153243 ↗ | Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes | Unknown status | John H. Stroger Hospital | Phase 4 | 2007-04-01 | Recent clinical trials in non diabetics showed that vitamin D supplementation markedly reduced serum levels of C-reactive protein (CRP), interleukin-6, and tissue matrix metallo-proteinases. Our study objective is to evaluate if administration of vitamin D in African Americans with hypovitaminosis D and DM Type 2 decreases serum levels of inflammatory/thrombotic markers such as CRP: Highly Sensitive C Reactive Protein. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DRISDOL
Condition Name
Clinical Trial Locations for DRISDOL
Trials by Country
Clinical Trial Progress for DRISDOL
Clinical Trial Phase
Clinical Trial Sponsors for DRISDOL
Sponsor Name
